Dilafor AB

dilaforCEO:  Lena Degling Wikingsson

Web:  www.dilafor.com

The company develops New Chemical Entities by modifying heparin. Two of these Heparin are now in clinical phases of development; DF01 is intended for the prevention and treatment of slow progress of birth labour. DF02 is diminishing severe clinical manifestations in malaria.

Share Button